Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG09222 Effect on PACAP38- and VIP-Induced Headache
NCT04976309Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jul 2021
- Primary completion
- Sep 2021
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lu ag09222 in migraine (3 arms), sponsored by Lundbeck. Primary endpoint: Area under the curve (AUC) of change from start of infusion in superficial temporal artery (STA) diameter from 0 to 120 min after start of infusion of PACAP38. Started Jul 2021; status: completed.
02
Drugs
lu ag09222
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04976309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976309.